JP2023542286A - 低酸素活性化ｄｎａアルキル化剤およびその医学的使用 - Google Patents

低酸素活性化ｄｎａアルキル化剤およびその医学的使用 Download PDF

Info

Publication number
JP2023542286A
JP2023542286A JP2023515576A JP2023515576A JP2023542286A JP 2023542286 A JP2023542286 A JP 2023542286A JP 2023515576 A JP2023515576 A JP 2023515576A JP 2023515576 A JP2023515576 A JP 2023515576A JP 2023542286 A JP2023542286 A JP 2023542286A
Authority
JP
Japan
Prior art keywords
compound
cancer
tumor
group
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542286A5 (https=
Inventor
リ、アンロン
デュアン、ジャンーシン
モン、ファンイン
ツァイ、シャオホン
チ、テンヤン
Original Assignee
アセンタウィッツ ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アセンタウィッツ ファーマシューティカルズ リミテッド filed Critical アセンタウィッツ ファーマシューティカルズ リミテッド
Publication of JP2023542286A publication Critical patent/JP2023542286A/ja
Publication of JP2023542286A5 publication Critical patent/JP2023542286A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2023515576A 2019-12-20 2021-06-23 低酸素活性化ｄｎａアルキル化剤およびその医学的使用 Pending JP2023542286A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911324466 2019-12-20
CNPCT/CN2020/114519 2020-09-10
PCT/CN2020/114519 WO2021120717A1 (zh) 2019-12-20 2020-09-10 抗癌化合物及其医药用途
PCT/CN2021/101870 WO2022052564A1 (zh) 2019-12-20 2021-06-23 乏氧活化的dna烷化剂及其医药用途

Publications (2)

Publication Number Publication Date
JP2023542286A true JP2023542286A (ja) 2023-10-06
JP2023542286A5 JP2023542286A5 (https=) 2023-11-02

Family

ID=76477075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515576A Pending JP2023542286A (ja) 2019-12-20 2021-06-23 低酸素活性化ｄｎａアルキル化剤およびその医学的使用

Country Status (7)

Country Link
US (2) US20230026163A1 (https=)
EP (2) EP4079738A4 (https=)
JP (1) JP2023542286A (https=)
KR (1) KR20230065309A (https=)
CN (2) CN114466853B (https=)
TW (4) TWI837402B (https=)
WO (2) WO2021120717A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
EP4428138A4 (en) * 2021-11-05 2025-08-27 Ascentawits Pharmaceuticals Ltd AKR1C3-ACTIVATED DNA ALKYLATING AGENT AND ITS MEDICAL USE
CN114106042B (zh) * 2021-11-12 2022-09-16 深圳艾欣达伟医药科技有限公司 一种氘代化合物及其制备方法和应用
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN115626938B (zh) * 2022-09-02 2026-04-17 温州医科大学 一种化合物rx4及其在抗结肠癌药物中的作用
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
KR20260009356A (ko) * 2023-05-11 2026-01-19 아센타위츠 파마슈티컬즈 리미티드 주사액 제제 및 이의 제조 방법, 및 상용성 약액 및 이의 제조 방법
WO2025026214A1 (zh) 2023-07-28 2025-02-06 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004130A1 (en) * 1999-07-14 2001-01-18 Purdue Research Foundation Phosphoramide compounds
CN107118231A (zh) * 2017-03-17 2017-09-01 北京大学 萘醌磷酰胺类化合物及其在作为细胞铁死亡诱导剂中的用途
JP2018513876A (ja) * 2015-03-10 2018-05-31 アセンタ ファーマシューティカルズ リミテッド Ｄｎａアルキル化剤
JP2018517710A (ja) * 2015-11-16 2018-07-05 アセンタ ファーマシューティカルズ リミテッド （ｒ）−および（ｓ）−１−（３−（３−ｎ，ｎ−ジメチルアミノカルボニル）フェノキシル−４−ニトロフェニル）−１−エチル−ｎ，ｎ’−ビス（エチレン）ホスホルアミデート、組成物ならびにその使用方法および製造方法
JP2018527301A (ja) * 2015-06-24 2018-09-20 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド Ｄｎａアルキル化剤を含有するアジリジン
WO2019062919A1 (en) * 2017-09-29 2019-04-04 Obi Pharma, Inc. METHOD OF TREATING LEUKEMIA
WO2020022868A1 (ko) * 2018-07-27 2020-01-30 에스케이이노베이션 주식회사 입자 균일도가 우수한 모데나이트 제올라이트 및 그 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617398A (en) * 1982-04-12 1986-10-14 The Research Foundation Of State University Of New York Phosphoaziridine compounds useful for treatment of tumors
WO2004062596A2 (en) * 2003-01-09 2004-07-29 Zeneus Pharma Limited Antineoplastic ether lipid compounds having a four carbon backbone
AU2005325676A1 (en) * 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CA2592118C (en) * 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
CN1948311A (zh) * 2006-11-09 2007-04-18 上海交通大学 2－碘代苯基－6－三氟甲基咪唑并[1,2－a]吡啶－3－乙酰胺类化合物及制备方法
US9278904B2 (en) * 2013-12-31 2016-03-08 Chemapotheca, Llc Synthesis of chiral amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds
CN104098432B (zh) * 2014-06-30 2016-03-30 福建师范大学福清分校 一种三氟甲基化芳烃的合成方法
CN106279321A (zh) 2016-08-09 2017-01-04 南京医科大学 吉西他滨ProTide乏氧活化前药及其应用
WO2018184003A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
CN107513057A (zh) 2017-09-06 2017-12-26 南京医科大学 一类乐伐替尼的乏氧活化前药及其应用
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004130A1 (en) * 1999-07-14 2001-01-18 Purdue Research Foundation Phosphoramide compounds
JP2018513876A (ja) * 2015-03-10 2018-05-31 アセンタ ファーマシューティカルズ リミテッド Ｄｎａアルキル化剤
JP2018527301A (ja) * 2015-06-24 2018-09-20 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド Ｄｎａアルキル化剤を含有するアジリジン
JP2018517710A (ja) * 2015-11-16 2018-07-05 アセンタ ファーマシューティカルズ リミテッド （ｒ）−および（ｓ）−１−（３−（３−ｎ，ｎ−ジメチルアミノカルボニル）フェノキシル−４−ニトロフェニル）−１−エチル−ｎ，ｎ’−ビス（エチレン）ホスホルアミデート、組成物ならびにその使用方法および製造方法
CN107118231A (zh) * 2017-03-17 2017-09-01 北京大学 萘醌磷酰胺类化合物及其在作为细胞铁死亡诱导剂中的用途
WO2019062919A1 (en) * 2017-09-29 2019-04-04 Obi Pharma, Inc. METHOD OF TREATING LEUKEMIA
WO2020022868A1 (ko) * 2018-07-27 2020-01-30 에스케이이노베이션 주식회사 입자 균일도가 우수한 모데나이트 제올라이트 및 그 제조방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GLOBAL JOURNAL OF PHARMACY & PHARMACEUTICAL SCIENCE, vol. 1, no. 4, JPN6022042651, 2017, pages 79 - 90, ISSN: 0005661515 *
MEDCHEM NEWS, vol. Vol. 41, No. 2, WINDOW, JPN6022042653, 2014, pages 8 - 22, ISSN: 0005661516 *
ファルマシア, vol. 50, no. 1, JPN6022055492, 2014, pages 14 - 18, ISSN: 0005661514 *

Also Published As

Publication number Publication date
TWI837402B (zh) 2024-04-01
WO2022052564A1 (zh) 2022-03-17
CN115667278A (zh) 2023-01-31
TW202128188A (zh) 2021-08-01
KR20230065309A (ko) 2023-05-11
TW202210083A (zh) 2022-03-16
WO2021120717A1 (zh) 2021-06-24
TW202421161A (zh) 2024-06-01
EP4079738A4 (en) 2024-04-24
TW202135831A (zh) 2021-10-01
CN114466853A (zh) 2022-05-10
CN114466853B (zh) 2026-04-14
US20230026163A1 (en) 2023-01-26
EP4079738A1 (en) 2022-10-26
US20230339991A1 (en) 2023-10-26
TWI833055B (zh) 2024-02-21
TWI893202B (zh) 2025-08-11
EP4212538A1 (en) 2023-07-19
EP4212538A4 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
JP2023542286A (ja) 低酸素活性化ｄｎａアルキル化剤およびその医学的使用
US12310968B2 (en) Chiral diaryl macrocycles and uses thereof
Duan et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs
TW201728583A (zh) 氨基噻唑化合物及其用途
CN111971070A (zh) Hsp90-靶向缀合物及其制剂
TW202320804A (zh) Akr1c3活化的dna烷化劑及其醫藥用途
TW202348235A (zh) 吉西他濱抗癌衍生物及抗癌醫藥用途
US20210046048A1 (en) Artemisinin Derivatives
CN113395968B (zh) 用于治疗疾病的fak抑制剂和btk抑制剂的组合
TW202510890A (zh) 治療brca突變癌症患者的方法
WO2016135140A1 (en) 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
CN121108109A (zh) 一种靶向alk蛋白的protac化合物及其抗肿瘤应用
HK1254606B (zh) 手性二芳基大环及其用途
Wang et al. Induction of Hmox1 as a Potential Covalent Inhibitor to Overcome Egfr T790m
CN105037399A (zh) 一类Bcr-Abl双倍体抑制剂及制备方法与用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250812